# Junta clínica — PT-pseudo_394e0b8dbeeb (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_394e0b8dbeeb",
  "pid": "PT-pseudo_394e0b8dbeeb",
  "task": 1,
  "psa": 9.2,
  "age": 71,
  "months": 3,
  "pirads": "4",
  "psad": 0.17,
  "psav": 1.1,
  "psap": 10.1,
  "vol": 53.0,
  "dre": "Nodus",
  "bx": "Negative",
  "cspca": 0.78939086,
  "medhx": "Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30), Benign prostatic hyperplasia",
  "meds": "atorvastatin, simvastatin, rosuvastatin, aspirin 80 mg, metoprolol, tamsulosin",
  "notes": "PSA 9.2 ng/mL. PI-RADS 4. PSAD 0.17. Prostate volume 53 mL. DRE nodus. csPCa 0.79.",
  "pmhx": [
    "Hypercholesterolaemia",
    "Coronary artery disease",
    "Obesity (BMI >30)",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "93 kg",
    "height": "164 cm",
    "bmi": "34.6",
    "bp": "114/71 mmHg",
    "hr": "70 bpm",
    "smoking": "Current smoker (45 pack-yr)",
    "last_dental": "2 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "04 Jan 2025",
  "enc_ref": "Dr. E. Mulder (GP)",
  "enc_type": "Re-evaluation - prior negative biopsy",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Elevated PSA progression alongside a newly identified PI-RADS 4 lesion on multiparametric MRI has necessitated specialist re-assessment."
    },
    {
      "s": "History",
      "t": "Mr X, a 71-year-old harbour pilot (semi-retired), entered initial evaluation in early 2023 following an incidental PSA elevation. Lower urinary tract symptoms remain mild and are currently managed with tamsulosin, yielding an IPSS score of 7. He reports no haematuria or acute urinary retention. Cardiovascular comorbidities encompass coronary artery disease and hypercholesterolaemia, managed through a regimen of atorvastatin, simvastatin, rosuvastatin, aspirin 80 mg, and metoprolol. He is a Current smoker (45 pack-yr) but maintains physical activity by cycling roughly 30 kilometres three times weekly. Obesity (BMI >30) is present. He remains married and lives with his partner. An adult daughter handles his medical correspondence upon request. Aside from the urological investigations, he experiences stable bilateral knee discomfort stemming from years of deck work and recently visited a podiatrist for routine nail care. No systemic symptoms or unexplained weight loss are reported."
    },
    {
      "s": "Physical examination",
      "t": "DRE — prostate: asymmetrically enlarged, firm texture, discrete nodule palpable in the right mid-gland. General examination remains unremarkable, with stable vital signs and no evidence of palpable lymphadenopathy or abdominal masses."
    }
  ],
  "occupation": "harbour pilot (semi-retired)",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "Podiatry — routine foot care"
  ],
  "alcohol": "8 units / week",
  "exercise": "Cycling 3x/week, ~30 km",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Daughter manages communication; CC on letters with patient consent.",
  "mri_hospital": "Jeroen Bosch Ziekenhuis ('s-Hertogenbosch)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_394e0b8dbeeb
Task: 1

Encounter: Urology - outpatient on 04 Jan 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 71-year-old male
  - PSA: 9.2 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.17 ng/mL²
  - PSA velocity: 1.1 ng/mL/yr
  - Prior PSA: 10.1 ng/mL
  - Prostate volume: 53.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.78939086 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30), Benign prostatic hyperplasia
  - Problem list / PMHx: Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30), Benign prostatic hyperplasia
  - Current medication: atorvastatin, simvastatin, rosuvastatin, aspirin 80 mg, metoprolol, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 9.2 ng/mL. PI-RADS 4. PSAD 0.17. Prostate volume 53 mL. DRE nodus. csPCa 0.79.

Vitals: weight 93 kg, height 164 cm, BMI 34.6, BP 114/71 mmHg, HR 70 bpm. Smoking: Current smoker (45 pack-yr).

Chief complaint: Elevated PSA progression alongside a newly identified PI-RADS 4 lesion on multiparametric MRI has necessitated specialist re-assessment.

History: Mr X, a 71-year-old harbour pilot (semi-retired), entered initial evaluation in early 2023 following an incidental PSA elevation. Lower urinary tract symptoms remain mild and are currently managed with tamsulosin, yielding an IPSS score of 7. He reports no haematuria or acute urinary retention. Cardiovascular comorbidities encompass coronary artery disease and hypercholesterolaemia, managed through a regimen of atorvastatin, simvastatin, rosuvastatin, aspirin 80 mg, and metoprolol. He is a Current smoker (45 pack-yr) but maintains physical activity by cycling roughly 30 kilometres three times weekly. Obesity (BMI >30) is present. He remains married and lives with his partner. An adult daughter handles his medical correspondence upon request. Aside from the urological investigations, he experiences stable bilateral knee discomfort stemming from years of deck work and recently visited a podiatrist for routine nail care. No systemic symptoms or unexplained weight loss are reported.

Physical examination: DRE — prostate: asymmetrically enlarged, firm texture, discrete nodule palpable in the right mid-gland. General examination remains unremarkable, with stable vital signs and no evidence of palpable lymphadenopathy or abdominal masses.

Patient info: harbour pilot (semi-retired); Married; Lives with partner.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 8 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Podiatry — routine foot care.
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: BIOPSY   p(biopsy) = 0.80
  uncertainty  +/- 0.07 (95% CI 0.66-0.94); among patients it cannot tell apart the outcome was 0.72 of 1.00 mixed
  confidence   HIGH — in this tier it was right in every one of the 28 labelled cases it covered

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior negative biopsy. My criterion answers BIOPSY.

The criterion: repeat, targeted, when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for an unchanged PI-RADS 3 or lower picture. In the labelled series this criterion matched the reading urologist in 16 of 18 cases in exactly this situation.

Like the classifier, I have read ONLY the visible panel — not the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory panel. Departing from me needs a specific
finding from a document somebody actually opened, named out loud. Not a restatement of the
panel numbers I already used.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline discusses using PI-RADS thresholds to guide biopsy decisions, noting that a threshold of PI-RADS $\ge 3$ is used to trigger biopsy, which may miss some ISUP Grade Group 2 cancers in biopsy-naïve patients. It also mentions that increasing the threshold to PI-RADS $\ge 4$ would have avoided 59% of all biopsy procedures while missing 28% of detected ISUP Grade Group 2 cancers in biopsy-naïve patients.

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of biopsy is not sufficiently informed by the guideline because it does not account for the specific PI-RADS score of 4 in this case. The guideline suggests that the decision should be risk-adapted based on PI-RADS thresholds, which the classifier's variables alone cannot fully represent. Furthermore, the classifier ignores the context of the prior negative biopsy, which is a key variable in the guideline's risk stratification.

WHAT WE STILL NEED
The mpMRI prose - The mpMRI prose states the patient has a PI-RADS 4 lesion, which is a high-risk category that the guideline uses in its risk-adapted matrix. This fact is decisive because it dictates the risk level for the decision.
Prior biopsy status - The prior biopsy status is negative, which is a significant factor in the guideline as it influences the decision for repeat sampling.
PSA density - The PSA density of 0.17 ng/mL² is a variable the guideline uses in its risk-adapted matrix to guide the decision.
The mpMRI prose - The mpMRI prose does not compare against an earlier study, so the guideline suggests that a stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on the specific risk stratification provided by the PI-RADS 4 finding and the context of the prior negative biopsy.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> To establish the mpMRI prose regarding lesion characteristics and comparison to prior studies.
  psa_trend (get_psa_trend) -> To establish the PSA trajectory beyond the headline value.
  previous_notes (get_previous_notes) -> To establish the management context, including the prior negative biopsy result.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What does the mpMRI prose state regarding the lesion size, zone, and whether it is compared against an earlier study?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel. Dropped 1 question(s) that asked for a value already printed on the panel: "What is the PSA density, and how does this factor into the risk-adapted decision?" — the room can read it off intervention 1.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose states the lesion is a "12 mm hypointense focus within the right mid-gland, reaching toward the peripheral zone," and it is "not compared against an earlier study."
psa_trend
The PSA trajectory shows values of 7.0 ng/mL on "Apr 2023", 7.9 ng/mL on "Nov 2023", 6.5 ng/mL on "Jun 2024", and 9.2 ng/mL on "Jan 2025".
previous_notes
The previous notes establish that the patient had an initial PSA elevation in April 2023, a subsequent rise to 10.1 ng/mL in June 2024, and a prior negative biopsy.

WHAT I DID NOT OPEN
laboratory_results, because the moderator explicitly stated that the PSA density question was already on the panel and did not require a tool call.

WHAT THIS SUPPORTS
FOR sampling this patient now
The mpMRI prose indicates a PI-RADS 4 lesion, which is a high-risk category.
The previous notes confirm the context of a prior negative biopsy and an upward PSA trend.
AGAINST sampling this patient now
nothing

WHERE THIS LEANS
The findings strongly support proceeding with a biopsy given the PI-RADS 4 finding in the context of a prior negative biopsy.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar has answered the moderator's first question by pulling up the `radiology_report`, which states the lesion is a "12 mm hypointense focus within the right mid-gland, reaching toward the peripheral zone," and that it is "not compared against an earlier study."

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the EXPERT-CLASSIFIER's suggestion of BIOPSY because the mpMRI prose indicates a PI-RADS 4 lesion, which is a high-risk category that the guideline uses in its risk-adapted matrix.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the mpMRI prose state regarding the lesion size, zone, and whether it is compared against an earlier study? This is answered by the `radiology_report`, which states the lesion is a "12 mm hypointense focus within the right mid-gland, reaching toward the peripheral zone," and that it is "not compared against an earlier study."

Q2. What does the psa_trend state regarding the PSA trajectory beyond the headline value? This is answered by the `psa_trend`, which shows values of 7.0 ng/mL on "Apr 2023", 7.9 ng/mL on "Nov 2023", 6.5 ng/mL on "Jun 2024", and 9.2 ng/mL on "Jan 2025".

Q3. What does the previous_notes state regarding the management context, including the prior negative biopsy result? This is answered by the `previous_notes`, which establishes that the patient had an initial PSA elevation in April 2023, a subsequent rise to 10.1 ng/mL in June 2024, and a prior negative biopsy.

WHAT CARRIES WEIGHT, AND WHY
The guideline variables relevant here are the PI-RADS score of 4 because it dictates the risk level for the decision; the prior biopsy status because it is a significant factor in the guideline as it influences the decision for repeat sampling; and the PSA density of 0.17 ng/mL² because the guideline uses this in its risk-adapted matrix to guide the decision. The room has been leaning on the PI-RADS 4 finding, which the guideline supports, but the guideline does not explicitly support the decision without considering the prior negative biopsy context.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, as the combination of a PI-RADS 4 lesion and a prior negative biopsy strongly supports this action according to the clinical context provided.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Given the PI-RADS 4 finding on the mpMRI and the context of a prior negative biopsy, proceeding with a targeted biopsy is indicated to rule out a missed lesion. This decision is strongly supported by the cohort criterion and the guideline context, as the PI-RADS 4 score dictates a high-risk assessment. The PSA trend and prior negative status confirm the need for further investigation.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
